RECRUITINGINTERVENTIONAL
Hemithoracic Arc Radiotherapy Post Pleural Decortication
Hemithoracic Volumetric Modulated Arc Radiotherapy as Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma Phase II Trial
About This Trial
Malignant Pleural Mesothelioma is an aggressive and refractory disease , the most aggressive treatment plan offered to these patients include trimodalitiy approach with chemotherapy as the mainstay of treatment . the rationale of post operative Radiotherapy is to sterilize the post operative volume to reduce local failure meanwhile minimizing toxicities in this trial we are going to assess the safety and efficacy of Radiotherapy in Mesothelioma patients poat Pleural decortication
Who May Be Eligible (Plain English)
Who May Qualify:
- Evidence of metastatic disease.
- Underwent Pleural decortication.
- Able to provide willing to sign a consent form.
Who Should NOT Join This Trial:
- Poor pulmonary function tests.
- Recurrent or palliative cases.
- Inability to attend full course of Radiotherapy or follow up visits.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Evidence of metastatic disease.
* Underwent Pleural decortication.
* Able to provide informed consent.
Exclusion Criteria:
* Poor pulmonary function tests.
* Recurrent or palliative cases.
* Inability to attend full course of Radiotherapy or follow up visits.
Treatments Being Tested
RADIATION
hemithoracic Volumetric Arc Radiotherapy post Pleural decortication
post operative delivery of hemithoracic Volumetric Arc Radiotherapy
Locations (1)
national Cancer Institute Cairo university
Cairo, Fom Elkhalig, Egypt